The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
LAG-3: from molecular functions to clinical applications
Open accessAbstract
To prevent the destruction of tissues owing to excessive and/or inappropriate immune responses, immune cells are under strict check by various regulatory mechanisms at multiple points. Inhibitory coreceptors, including programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4), serve as critical checkpoints in restricting immune responses against self-tissues and tumor cells. Immune checkpoint inhibitors that block PD-1 and CTLA-4 pathways significantly improved the outcomes of patients with diverse cancer types and have revolutionized cancer treatment. However, response rates to such therapies are rather limited, and immune-related adverse events are also observed in a substantial patient population, leading to the urgent need for novel therapeutics with higher efficacy and lower toxicity. In addition to PD-1 and CTLA-4, a variety of stimulatory and inhibitory coreceptors are involved in the regulation of T cell activation. Such coreceptors are listed as potential drug targets, and the competition to develop novel immunotherapies targeting these coreceptors has been very fierce. Among such coreceptors, lymphocyte activation gene-3 (LAG-3) is expected as the foremost target next to PD-1 in the development of cancer therapy, and multiple clinical trials testing the efficacy of LAG-3-targeted therapy are underway. LAG-3 is a type I transmembrane protein with structural similarities to CD4. Accumulating evidence indicates that LAG-3 is an inhibitory coreceptor and plays pivotal roles in autoimmunity, tumor immunity, and anti-infection immunity. In this review, we summarize the current understanding of LAG-3, ranging from its discovery to clinical application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
Towards a systems understanding of MHC class I and MHC class II antigen presentation
Neefjes, J., Jongsma, M. L. M., Paul, P., & Bakke, O. (2011) · Nature Reviews Immunology · doi:10.1038/nri3084 · Cited by 2,044
The diverse functions of the PD1 inhibitory pathway
Sharpe, A. H., & Pauken, K. E. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.108 · Cited by 1,971
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
Khan, O., Giles, J. R., McDonald, S., Manne, S., Ngiow, S. F., Patel, K. P., Werner, M. T., Huang, A. C., Alexander, K. A., Wu, J. E., et al. (2019) · Nature · doi:10.1038/s41586-019-1325-x · Cited by 1,646
Role of LAG-3 in Regulatory T Cells
Huang, C.-T., Workman, C. J., Flies, D., Pan, X., Marson, A. L., Zhou, G., Hipkiss, E. L., Ravi, S., Kowalski, J., Levitsky, H. I., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.010 · Cited by 1,325
TOX is a critical regulator of tumour-specific T cell differentiation
Scott, A. C., Dündar, F., Zumbo, P., Chandran, S. S., Klebanoff, C. A., Shakiba, M., Trivedi, P., Menocal, L., Appleby, H., Camara, S., et al. (2019) · Nature · doi:10.1038/s41586-019-1324-y · Cited by 1,106
LAG-3, a novel lymphocyte activation gene closely related to CD4.
Triebel, F., Jitsukawa, S., Baixeras, E., Roman-Roman, S., Genevee, C., Viegas-Pequignot, E., & Hercend, T. (1990) · The Journal of experimental medicine · doi:10.1084/jem.171.5.1393 · Cited by 925
Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013) · Nature Immunology · doi:10.1038/ni.2762 · Cited by 916
Self-citationNR4A transcription factors limit CAR T cell function in solid tumours
Chen, J., López-Moyado, I. F., Seo, H., Lio, C.-W. J., Hempleman, L. J., Sekiya, T., Yoshimura, A., Scott-Browne, J. P., & Rao, A. (2019) · Nature · doi:10.1038/s41586-019-0985-x · Cited by 874
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Wang, J., Sanmamed, M. F., Datar, I., Su, T. T., Ji, L., Sun, J., Chen, L., Chen, Y., Zhu, G., Yin, W., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.010 · Cited by 871
Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, C., Qian, F., Lele, S., Shrikant, P., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003345107 · Cited by 859
The Transcription Factor NFAT Promotes Exhaustion of Activated CD8 + T Cells
Martinez, G. J., Pereira, R. M., Äijö, T., Kim, E. Y., Marangoni, F., Pipkin, M. E., Togher, S., Heissmeyer, V., Zhang, Y. C., Crotty, S., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.006 · Cited by 857
Seo, H., Chen, J., González-Avalos, E., Samaniego-Castruita, D., Das, A., Wang, Y. H., López-Moyado, I. F., Georges, R. O., Zhang, W., Onodera, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905675116 · Cited by 808
Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells
Gagliani, N., Magnani, C. F., Huber, S., Gianolini, M. E., Pala, M., Licona-Limon, P., Guo, B., Herbert, D. R., Bulfone, A., Trentini, F., et al. (2013) · Nature Medicine · doi:10.1038/nm.3179 · Cited by 793
Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3
Mao, X., Ou, M. T., Karuppagounder, S. S., Kam, T.-I., Yin, X., Xiong, Y., Ge, P., Umanah, G. E., Brahmachari, S., Shin, J.-H., et al. (2016) · Science · doi:10.1126/science.aah3374 · Cited by 690
Turner, J. M., Brodsky, M. H., Irving, B. A., Levin, S. D., Perlmutter, R. M., & Littman, D. R. (1990) · Cell · doi:10.1016/0092-8674(90)90090-2 · Cited by 621
Grosso, J. F., Kelleher, C. C., Harris, T. J., Maris, C. H., Hipkiss, E. L., De Marzo, A., Anders, R., Netto, G., Getnet, D., Bruno, T. C., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31184 · Cited by 547
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
Andrews, L. P., Yano, H., & Vignali, D. A. A. (2019) · Nature Immunology · doi:10.1038/s41590-019-0512-0 · Cited by 543
Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction
Liu, X., Wang, Y., Lu, H., Li, J., Yan, X., Xiao, M., Hao, J., Alekseev, A., Khong, H., Chen, T., et al. (2019) · Nature · doi:10.1038/s41586-019-0979-8 · Cited by 533
Kouo, T., Huang, L., Pucsek, A. B., Cao, M., Solt, S., Armstrong, T., & Jaffee, E. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0150 · Cited by 531
Giraldo, N. A., Becht, E., Pagès, F., Skliris, G., Verkarre, V., Vano, Y., Mejean, A., Saint-Aubert, N., Lacroix, L., Natario, I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2926 · Cited by 507
Man, K., Gabriel, S. S., Liao, Y., Gloury, R., Preston, S., Henstridge, D. C., Pellegrini, M., Zehn, D., Berberich-Siebelt, F., Febbraio, M. A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.021 · Cited by 506
T cell receptor signalling in the control of regulatory T cell differentiation and function
Li, M. O., & Rudensky, A. Y. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.26 · Cited by 493 · cited 1×
“40 Zhang et al 41 demonstrated that LAG-3 on T reg cells limited their proliferation intrinsically.”
Kao, C., Oestreich, K. J., Paley, M. A., Crawford, A., Angelosanto, J. M., Ali, M.-A. A., Intlekofer, A. M., Boss, J. M., Reiner, S. L., Weinmann, A. S., et al. (2011) · Nature Immunology · doi:10.1038/ni.2046 · Cited by 484
Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection
Butler, N. S., Moebius, J., Pewe, L. L., Traore, B., Doumbo, O. K., Tygrett, L. T., Waldschmidt, T. J., Crompton, P. D., & Harty, J. T. (2012) · Nature Immunology · doi:10.1038/ni.2180 · Cited by 482
Shin, H., Blackburn, S. D., Intlekofer, A. M., Kao, C., Angelosanto, J. M., Reiner, S. L., & Wherry, E. J. (2009) · Immunity · doi:10.1016/j.immuni.2009.06.019 · Cited by 481
Baixeras, E., Huard, B., Miossec, C., Jitsukawa, S., Martin, M., Hercend, T., Auffray, C., Triebel, F., & Piatier-Tonneau, D. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.2.327 · Cited by 397
Thommen, D. S., Schreiner, J., Müller, P., Herzig, P., Roller, A., Belousov, A., Umana, P., Pisa, P., Klein, C., Bacac, M., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0097 · Cited by 395
Huard, B., Prigent, P., Tournier, M., Bruniquel, D., & Triebel, F. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250949 · Cited by 391
Cutting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-3
Workman, C. J., Dugger, K. J., & Vignali, D. A. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5392 · Cited by 389 · cited 1×
“Workman et al 13 reported that the lysine residue of the KIEELE sequence is required for the LAG-3-mediated inhibition of the antigen-dependent activation of 3A9 hybridoma T cells.”
Xu, F., Liu, J., Liu, D., Liu, B., Wang, M., Hu, Z., Du, X., Tang, L., & He, F. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2690 · Cited by 373
Camisaschi, C., Casati, C., Rini, F., Perego, M., De Filippo, A., Triebel, F., Parmiani, G., Belli, F., Rivoltini, L., & Castelli, C. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903879 · Cited by 350 · cited 1×
“92 93 Such LAG-3-expressing T reg cells produce high levels of immunoregulatory cytokines IL-10 and TGF-β and suppress tumor-specific T cells.”
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
Okazaki, T., Okazaki, I.-M., Wang, J., Sugiura, D., Nakaki, F., Yoshida, T., Kato, Y., Fagarasan, S., Muramatsu, M., Eto, T., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100466 · Cited by 324
Self-citationLAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis
Workman, C. J., Wang, Y., El Kasmi, K. C., Pardoll, D. M., Murray, P. J., Drake, C. G., & Vignali, D. A. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0800185 · Cited by 316
Characterization of the major histocompatibility complex class II binding site on LAG-3 protein
Huard, B., Mastrangeli, R., Prigent, P., Bruniquel, D., Donini, S., El-Tayar, N., Maigret, B., Dréano, M., & Triebel, F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5744 · Cited by 308
Huang, R.-Y., Eppolito, C., Lele, S., Shrikant, P., Matsuzaki, J., & Odunsi, K. (2015) · Oncotarget · doi:10.18632/oncotarget.4751 · Cited by 308
Metalloproteases regulate T‐cell proliferation and effector function via LAG‐3
Li, N., Wang, Y., Forbes, K., Vignali, K. M., Heale, B. S., Saftig, P., Hartmann, D., Black, R. A., Rossi, J. J., Blobel, C. P., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601520 · Cited by 282
LAG-3 Inhibitory Receptor Expression Identifies Immunosuppressive Natural Regulatory Plasma Cells
Lino, A. C., Dang, V. D., Lampropoulou, V., Welle, A., Joedicke, J., Pohar, J., Simon, Q., Thalmensi, J., Baures, A., Flühler, V., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.007 · Cited by 277
Maruhashi, T., Okazaki, I.-M., Sugiura, D., Takahashi, S., Maeda, T. K., Shimizu, K., & Okazaki, T. (2018) · Nature Immunology · doi:10.1038/s41590-018-0217-9 · Cited by 275
Self-citationExpression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells
Kisielow, M., Kisielow, J., Capoferri-Sollami, G., & Karjalainen, K. (2005) · European Journal of Immunology · doi:10.1002/eji.200526090 · Cited by 271
He, Y., Yu, H., Rozeboom, L., Rivard, C. J., Ellison, K., Dziadziuszko, R., Suda, K., Ren, S., Wu, C., Hou, L., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.019 · Cited by 268
Shaw, A. S., Chalupny, J., Whitney, J. A., Hammond, C., Amrein, K. E., Kavathas, P., Sefton, B. M., & Rose, J. K. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.5.1853 · Cited by 259
Gandhi, M. K., Lambley, E., Duraiswamy, J., Dua, U., Smith, C., Elliott, S., Gill, D., Marlton, P., Seymour, J., & Khanna, R. (2006) · Blood · doi:10.1182/blood-2006-04-015164 · Cited by 255
Brignone, C., Gutierrez, M., Mefti, F., Brain, E., Jarcau, R., Cvitkovic, F., Bousetta, N., Medioni, J., Gligorov, J., Grygar, C., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-71 · Cited by 255
LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination
Triebel, F. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.10.001 · Cited by 225
Galectin 3 as a guardian of the tumor microenvironment
Ruvolo, P. P. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.08.008 · Cited by 224
Yang, Z.-Z., Kim, H. J., Villasboas, J. C., Chen, Y.-P., Price-Troska, T., Jalali, S., Wilson, M., Novak, A. J., & Ansell, S. M. (2017) · Oncotarget · doi:10.18632/oncotarget.18251 · Cited by 213
CD4+CD25−LAG3+regulatory T cells controlled by the transcription factor Egr-2
Okamura, T., Fujio, K., Shibuya, M., Sumitomo, S., Shoda, H., Sakaguchi, S., & Yamamoto, K. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906872106 · Cited by 212
Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma
Goding, S. R., Wilson, K. A., Xie, Y., Harris, K. M., Baxi, A., Akpinarli, A., Fulton, A., Tamada, K., Strome, S. E., & Antony, P. A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300271 · Cited by 206
Burugu, S., Gao, D., Leung, S., Chia, S. K., & Nielsen, T. O. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx557 · Cited by 189
Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo
Durham, N. M., Nirschl, C. J., Jackson, C. M., Elias, J., Kochel, C. M., Anders, R. A., & Drake, C. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109080 · Cited by 178
Deng, W.-W., Mao, L., Yu, G.-T., Bu, L.-L., Ma, S.-R., Liu, B., Gutkind, J. S., Kulkarni, A. B., Zhang, W.-F., & Sun, Z.-J. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1239005 · Cited by 172
Cutting Edge: Accelerated Autoimmune Diabetes in the Absence of LAG-3
Bettini, M., Szymczak-Workman, A. L., Forbes, K., Castellaw, A. H., Selby, M., Pan, X., Drake, C. G., Korman, A. J., & Vignali, D. A. A. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100714 · Cited by 169
Attributes of γδ intraepithelial lymphocytes as suggested by their transcriptional profile
Fahrer, A. M., Konigshofer, Y., Kerr, E. M., Ghandour, G., Mack, D. H., Davis, M. M., & Chien, Y.-H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171320798 · Cited by 168
Characterization of a Novel C-type Lectin-like Gene, LSECtin
Liu, W., Tang, L., Zhang, G., Wei, H., Cui, Y., Guo, L., Gou, Z., Chen, X., Jiang, D., Zhu, Y., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311227200 · Cited by 166
Tian, X., Zhang, A., Qiu, C., Wang, W., Yang, Y. Z., Qiu, C., Liu, A., Zhu, L., Yuan, S., Hu, H., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402176 · Cited by 164
LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes
Zhang, Q., Chikina, M., Szymczak-Workman, A. L., Horne, W., Kolls, J. K., Vignali, K. M., Normolle, D., Bettini, M., Workman, C. J., & Vignali, D. A. A. (2017) · Science Immunology · doi:10.1126/sciimmunol.aah4569 · Cited by 164
Denning, T. L., Granger, S., Mucida, D., Graddy, R., Leclercq, G., Zhang, W., Honey, K., Rasmussen, J. P., Cheroutre, H., Rudensky, A. Y., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4230 · Cited by 160
Dong, Y., Li, X., Zhang, L., Zhu, Q., Chen, C., Bao, J., & Chen, Y. (2019) · BMC Immunology · doi:10.1186/s12865-019-0309-9 · Cited by 155
Ascierto, P. A., Bono, P., Bhatia, S., Melero, I., Nyakas, M., Svane, I. M., Larkin, J., Gomez‐Roca, C., Schadendorf, D., Dummer, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440.011 · Cited by 150
Li, F., Zhang, Y., Jin, G., Yao, L., & Wu, D. (2012) · Immunology Letters · doi:10.1016/j.imlet.2012.12.004 · Cited by 147
Biochemical Analysis of the Regulatory T Cell Protein Lymphocyte Activation Gene-3 (LAG-3; CD223)
Li, N., Workman, C. J., Martin, S., & Vignali, D. A. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.11.6806 · Cited by 146
Wierz, M., Pierson, S., Guyonnet, L., Viry, E., Lequeux, A., Oudin, A., Niclou, S. P., Ollert, M. W., Berchem, G., Janji, B., et al. (2018) · Blood · doi:10.1182/blood-2017-06-792267 · Cited by 146
TGF-β3-expressing CD4+CD25−LAG3+ regulatory T cells control humoral immune responses
Okamura, T., Sumitomo, S., Morita, K., Iwasaki, Y., Inoue, M., Nakachi, S., Komai, T., Shoda, H., Miyazaki, J., Fujio, K., et al. (2015) · Nature Communications · doi:10.1038/ncomms7329 · Cited by 142
On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection
Richter, K., Agnellini, P., & Oxenius, A. (2009) · International Immunology · doi:10.1093/intimm/dxp107 · Cited by 141
The effect of immune microenvironment on the progression and prognosis of colorectal cancer
Chen, J., & Chen, Z. (2014) · Medical Oncology · doi:10.1007/s12032-014-0082-9 · Cited by 140
Avice, M.-N., Sarfati, M., Triebel, F., Delespesse, G., & Demeure, C. E. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.5.2748 · Cited by 132
Maeda, T. K., Sugiura, D., Okazaki, I., Maruhashi, T., & Okazaki, T. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.007455 · Cited by 129
Self-citationThe role of semaphorins in immune responses and autoimmune rheumatic diseases
Nishide, M., & Kumanogoh, A. (2018) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.201 · Cited by 115
Avice, M.-N., Sarfati, M., Triebel, F., et al. (1999) · PubMed · Cited by 114
Bae, J., Lee, S. J., Park, C., Lee, Y. S., & Chun, T. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401025 · Cited by 114
Kraman, M., Faroudi, M., Allen, N. L., Kmiecik, K., Gliddon, D., Seal, C. J., Koers, A., Wydro, M. M., Batey, S., Winnewisser, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3548 · Cited by 113
Identification of palmitoylation sites on CD4, the human immunodeficiency virus receptor.
Crise, B. J., & Rose, J. K. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42253-3 · Cited by 112
Kadowaki, A., Miyake, S., Saga, R., Chiba, A., Mochizuki, H., & Yamamura, T. (2016) · Nature Communications · doi:10.1038/ncomms11639 · Cited by 110
Demeure, C. E., Wolfers, J., Martin‐Garcia, N., Gaulard, P., & Triebel, F. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00184-8 · Cited by 109
Bruniquel, D., Borie, N., Hannier, S., & Triebel, F. (1998) · Immunogenetics · doi:10.1007/s002510050411 · Cited by 108
Keane, C., Law, S. C., Gould, C., Birch, S. E., Sabdia, M. B., de Long, L. M., Thillaiyampalam, G., Abro, E. U., Tobin, J. W. D., Tan, X., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001390 · Cited by 106
Sega, E. I., Leveson-Gower, D. B., Florek, M., Schneidawind, D., Luong, R. H., & Negrin, R. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086551 · Cited by 100
Wang‐Gillam, A., Plambeck-Suess, S. M., Goedegebuure, P. S., Simon, P. O., Mitchem, J. B., Hornick, J. R., Sorscher, S. M., Picus, J., Suresh, R., Lockhart, A. C., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9866-y · Cited by 98
Wu, J., Zhang, H., Shi, X., Xiao, X., Fan, Y., Minze, L. J., Wang, J., Ghobrial, R. M., Xia, J., Sciammas, R., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.003 · Cited by 98
Iouzalen, N., Andreae, S., Hannier, S., & Triebel, F. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(2001010)31:10<2885::aid-immu2885>3.0.co;2-2 · Cited by 96
Legat, A., Hajjami, H. M.-E., Baumgaertner, P., Cagnon, L., Maillard, S. A., Geldhof, C., Iancu, E. M., Lebon, L., Guillaume, P., Dojcinovic, D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1212 · Cited by 93
Romano, E., Michielin, O. A., Voelter, V., Laurent, J., Bichat, H., Stravodimou, A., Romero, P. J., Speiser, D. E., Triebel, F., Leyvraz, S., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-97 · Cited by 84
LAG3 Expression in Active Mycobacterium tuberculosis Infections
Phillips, B., Mehra, S., Ahsan, M. H., Selman, M., Khader, S. A., & Kaushal, D. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.11.003 · Cited by 81
Rudd, C. E., Chanthong, K., & Taylor, A. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.076 · Cited by 77
Wei, T., Zhang, J., Qin, Y., Wu, Y. C., Zhu, L. X., Lu, L., Tang, G., & Shen, Q. (2015) · Europe PMC (PubMed Central) · Cited by 75
Double negative T cells mediate Lag3-dependent antigen-specific protection in allergic asthma
Tian, D., Yang, L., Wang, S., Zhu, Y., Shi, W., Zhang, C., Jin, H., Tian, Y., Xu, H., Sun, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12243-0 · Cited by 75
Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.
Hong, D. S., Schöffski, P., Calvo, A., Sarantopoulos, J., de Olza, M. O., Carvajal, R. D., Prawira, A., Kyi, C., Esaki, T., Akerley, W., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3012 · Cited by 72
Sun, H., Sun, C., & Xiao, W. (2013) · Cytokine · doi:10.1016/j.cyto.2013.09.016 · Cited by 66
LAG-3 expression on tumor-infiltrating T cells in soft tissue sarcoma correlates with poor survival
Que, Y., Zhixin, F., Guan, Y., Wei, X., Bushu, X., Jingjing, Z., Huoying, C., Xinke, Z., Zeng, M., Yao, L., et al. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0306 · Cited by 60
Buisson, S., & Triebel, F. (2003) · Vaccine · doi:10.1016/s0264-410x(02)00533-9 · Cited by 55
Lymphocyte Activation Gene-3 (LAG-3) Negatively Regulates Environmentally-Induced Autoimmunity
Jha, V., Workman, C. J., McGaha, T. L., Li, L., Vas, J., Vignali, D. A. A., & Monestier, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104484 · Cited by 52
A LAG-3–Specific Agonist Antibody for the Treatment of T Cell–Induced Autoimmune Diseases
Angin, M., Brignone, C., & Triebel, F. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900823 · Cited by 51
Byun, H., Jung, W., Lee, D., Kim, S., Kim, S. J., Park, C., Chung, H. Y., & Chun, T. (2006) · Cell Biology International · doi:10.1016/j.cellbi.2006.11.002 · Cited by 46
Erickson, J. J., Rogers, M. C., Tollefson, S. J., Boyd, K. L., & Williams, J. V. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502115 · Cited by 46
Kim, D., Le, H. T., Nguyen, Q. T., Kim, S., Lee, J., & Min, B. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800898 · Cited by 46
Roy, S., Coulon, P.-G. A., Srivastava, R., Vahed, H., Kim, G. J., Walia, S. S., Yamada, T., Fouladi, M. A., Ly, V. T., & BenMohamed, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02922 · Cited by 39
LAG-3 is not responsible for selecting T helper cells in CD4-deficient mice
Miyazaki, T., Dierich, A., Benoist, C. O., & Mathis, D. J. (1996) · International Immunology · doi:10.1093/intimm/8.5.725 · Cited by 38
Poirier, N., Haudebourg, T., Brignone, C., Dilek, N., Hervouet, J., Minault, D., Coulon, F., de Silly, R. V., Triebel, F., Blancho, G., et al. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04329.x · Cited by 37
Regulation of immune and neural function via leukocyte Ig-like receptors
Takeda, K., & Nakamura, A. (2017) · The Journal of Biochemistry · doi:10.1093/jb/mvx036 · Cited by 34
LAG-3 Confers a Competitive Disadvantage upon Antiviral CD8+ T Cell Responses
Cook, K. D., & Whitmire, J. K. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1401594 · Cited by 32
Motte-Mohs, R. N. L., Shah, K., Smith, D., Gorlatov, S. N., Ciccarone, V. C., Tamura, J. K., Li, H., Rillema, J. R., Licea, M., He, L., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-3217 · Cited by 30
Chen, N., Liu, Y., Guo, Y., Chen, Y., Liu, X., & Liu, M. (2015) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13017 · Cited by 25
Savitsky, D. A., Ward, R., Riordan, C., Mundt, C., Jennings, S., Connolly, J., Findeis, M. A., Sanicola, M., Underwood, D. J., Nastri, H. G., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-3819 · Cited by 23
Stimulatory and Inhibitory Co-signals in Autoimmunity
Okazaki, T., & Okazaki, I. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_8 · Cited by 12
Self-citationZettl, M., Wurm, M., Schaaf, O., Tirapu, I., Mostböck, S., Reschke, M., Schmidbauer, S.-M., Frego, L., Lorenz, I. C., Thibodeau, M. S., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-4547 · Cited by 4
Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3)
(2002) · doi:10.1002/1521-4141(200208)32:8<2255::aid-immu2255>3.0.co;2-a
Cited by
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
Kraehenbuehl, L., Weng, C.-H., Eghbali, S., Wolchok, J. D., & Merghoub, T. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00552-7 · Cited by 846
Glioma targeted therapy: insight into future of molecular approaches
Yang, K., Wu, Z., Zhang, H., Zhang, N., Wu, W., Wang, Z., Dai, Z., Zhang, X., Zhang, L., Peng, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01513-z · Cited by 704
Huang, A. C., & Zappasodi, R. (2022) · Nature Immunology · doi:10.1038/s41590-022-01141-1 · Cited by 571
Immunotherapy: Reshape the Tumor Immune Microenvironment
LV, B., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 482
Metadata
- Authors
- Maruhashi, T., Sugiura, D., Okazaki, I.-M., & Okazaki, T.
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2020-09
- Volume
- 8
- Issue
- 2
- Pages
- e001014
- ISSN
- 2051-1426 (ISSN-L)
- OpenAlex
- W3085860981
- Cited by
- 459
- References
- 116
- FWCI
- 20.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.